热门资讯> 正文
BriaCell Thereutics将Bria-MEL+全细胞黑色素瘤免疫治疗候选疫苗推向临床开发，具有关键的基因工程里程碑
2026-08-24 19:33
- Cell-based immunotherapy program is designed to harness patients’ own immune systems
- Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturing
- Program builds on BriaCell’s experience in metastatic breast cancer and prostate cancer, further expanding its therapeutic vaccine platform
- Melanoma remains a significant unmet medical need, with approximately 112,000 new cases and 8,510 deaths expected in the US in 2026
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
